New engineered immune cell therapy tested for tough liver cancers
NCT ID NCT05155189
Summary
This early-stage study is testing a new type of cell therapy called C-CAR031 for people with advanced liver cancer that has not responded to standard treatments. Doctors will collect and modify a patient's own immune cells to better attack cancer, then infuse them back. The main goals are to see if the treatment is safe and if it can shrink tumors, either alone or combined with other cancer drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of Zhengzhou University
RECRUITINGZhengzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.